Erasca (ERAS) Change in Acquisitions & Divestments (2020 - 2026)
Erasca (ERAS) reported Change in Acquisitions & Divestments of $100.8 million for Q1 2026, up 124.06% on a YoY basis from $45.0 million in Q1 2025, and up 50.6% quarter-over-quarter from $67.0 million in Q4 2025.
Erasca (ERAS) Change in Acquisitions & Divestments (2020 - 2026) Analysis & Trends
Erasca has reported Change in Acquisitions & Divestments for 7 years, with the latest figure at $100.8 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 124.06% year-over-year to $100.8 million; the trailing twelve-month figure through Mar 2026 stood at $316.9 million (up 21.71% YoY), and the FY2025 full-year result was $261.0 million, down 3.08% from the prior year.
- Change in Acquisitions & Divestments for Q1 2026 stood at $100.8 million, up from $67.0 million in the prior quarter.
- The five-year high for Change in Acquisitions & Divestments was $100.8 million in Q1 2026, with the low at $7.9 million in Q2 2022.
- Historically, Change in Acquisitions & Divestments has averaged $56.2 million across 5 years, with a median of $60.2 million in 2023.
- Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments slumped 47.19% — and 2023, when it jumped 744.94%.
- Erasca's Change in Acquisitions & Divestments stood at $33.9 million in 2022, then soared by 93.94% to $65.7 million in 2023, then jumped by 36.51% to $89.8 million in 2024, then decreased by 25.4% to $67.0 million in 2025, then surged by 50.6% to $100.8 million in 2026.
- The last three Change in Acquisitions & Divestments figures came in at $100.8 million (Q1 2026), $67.0 million (Q4 2025), and $71.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Erasca | 4.28 Bn | 4.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100.83 Mn |
| Mar 31, 2026 | 100.83 Mn |
| Dec 31, 2025 | 66.95 Mn |
| Dec 31, 2025 | 66.95 Mn |
| Sep 30, 2025 | 71.25 Mn |
| Sep 30, 2025 | 71.25 Mn |
| Jun 30, 2025 | 77.83 Mn |
| Jun 30, 2025 | 77.83 Mn |
| Mar 31, 2025 | 45.00 Mn |
| Mar 31, 2025 | 45.00 Mn |
| Dec 31, 2024 | 89.75 Mn |
| Dec 31, 2024 | 89.75 Mn |
| Sep 30, 2024 | 89.33 Mn |
| Sep 30, 2024 | 89.33 Mn |
| Jun 30, 2024 | 36.25 Mn |
| Jun 30, 2024 | 36.25 Mn |
| Mar 31, 2024 | 54.00 Mn |
| Mar 31, 2024 | 54.00 Mn |
| Dec 31, 2023 | 65.75 Mn |
| Dec 31, 2023 | 65.75 Mn |